KAS
CLDX icon

Kestra Advisory Services’s Celldex Therapeutics CLDX Stock Holding History

Kestra Advisory Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,600
Closed -$97.8K – 3335
2025
Q4 		$97.8K Buy
+3,600
New +$94.8K ﹤0.01% 3444

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Kestra Advisory Services's CLDX Position: Q1 2026 in Review

Kestra Advisory Services sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 3,600 shares — an estimated $97.8K sold.

Kestra Advisory Services first reported a position in CLDX in Q4 2025 and held it in 1 quarter. The position peaked at $97.8K in Q4 2025. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Kestra Advisory Services reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 3,600 Celldex Therapeutics shares in Q1 2026, an estimated $97.8K.
  • Kestra Advisory Services first reported a position in Celldex Therapeutics in Q4 2025 and held it in 1 quarter.
  • Kestra Advisory Services's Celldex Therapeutics position peaked at $97.8K in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.